PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pasireotide aspartate. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

11 hits

Bibliografisk träff 2012-10-24

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid HA, Libutti SK.

Surgery · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.surg.2012.08.021

Bibliografisk träff 2012-09-14

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B.

Endocr Relat Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1530/erc-11-0367

Bibliografisk träff 2012-09-01

Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies.

Kokona D, Mastrodimou N, Pediaditakis I, Charalampopoulos I, Schmid HA, Thermos K.

Exp Eye Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exer.2012.08.005

Bibliografisk träff 2012-05-23

Stimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro.

Pecori Giraldi F, Pagliardini L, Cassarino MF, Martucci F, Sesta A, Castelli L, Montanari E, Schmid HA, Cavagnini F.

Gen Comp Endocrinol · journal article · DOI 10.1016/j.ygcen.2012.05.003

Bibliografisk träff 2012-04-19

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M.

Drug Des Devel Ther · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.2147/dddt.s29125

Bibliografisk träff 2011-07-01

SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.

Xie Y, Chen S, Wang CH, Tang CW.

Cancer Biol Ther · journal article · DOI 10.4161/cbt.12.1.15730

Bibliografisk träff 2011-06-14

Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K.

J Clin Pharmacol · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1177/0091270011408727

Bibliografisk träff 2011-04-28

Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.

Castillo V, Theodoropoulou M, Stalla J, Gallelli MF, Cabrera-Blatter MF, Haedo MR, Labeur M, Schmid HA, Stalla GK, Arzt E.

Neuroendocrinology · research support, non-u.s. gov't; journal article · DOI 10.1159/000327429

Bibliografisk träff 2010-10-27

Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.

Mariniello B, Finco I, Sartorato P, Patalano A, Iacobone M, Guzzardo V, Fassina A, Mantero F.

J Endocrinol Invest · research support, non-u.s. gov't; journal article · DOI 10.1007/bf03346721

Bibliografisk träff 2010-07-16

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

Waser B, Cescato R, Tamma ML, Maecke HR, Reubi JC.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2010.07.005

Bibliografisk träff 2009-11-12

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, Schonbrunn A.

Mol Endocrinol · comparative study; research-article; journal article; research support, n.i.h., extramural · DOI 10.1210/me.2009-0321